Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study

dc.contributor.authorKalashnikov Ilja
dc.contributor.authorTanskanen Tomas
dc.contributor.authorViisanen Leevi
dc.contributor.authorMalila Nea
dc.contributor.authorJyrkkiö Sirkku
dc.contributor.authorLeppä Sirpa
dc.contributor.organizationfi=kliininen syöpätautioppi|en=Clinical Oncology|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code2607315
dc.converis.publication-id179702649
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/179702649
dc.date.accessioned2025-08-27T20:49:43Z
dc.date.available2025-08-27T20:49:43Z
dc.description.abstract<p>Marginal zone lymphoma (MZL) is an indolent B-cell malignancy with heterogeneous anatomical and clinical presentation. While MZLs are generally associated with long survival, some patients experience histological transformation to aggressive large B-cell lymphoma. Population-based long-term data on the transformation of MZL is limited. We conducted a nationwide population-based study to estimate the risk of transformation and relative survival in patients diagnosed with MZL in Finland from 1995-2018. We identified a total of 1454 patients with MZL from the Finnish Cancer Registry (FCR). The cumulative incidence of transformation was 4.7% (95% CI, 3.6-6.2) at 10 years. The highest incidence of transformation was observed in the patients with splenic MZL (14.0%; 95% CI, 8.6-22.7). The transformation was associated with a substantially increased risk of death (HR, 5.18; 95% CI, 3.58-7.50). Ten-year relative survival was 79% (95% CI, 73-83%). Transformation, nodal MZL subtype, and older age at diagnosis were associated with increased excess mortality, whereas patients diagnosed at a later calendar period had a lower excess risk of death. We conclude that transformation resulted in a substantially increased mortality irrespective of MZL subtype compared with the patients without transformation. Our results also suggest a reduction in excess mortality in recent years.</p>
dc.identifier.eissn2044-5385
dc.identifier.jour-issn2044-5385
dc.identifier.olddbid200307
dc.identifier.oldhandle10024/183334
dc.identifier.urihttps://www.utupub.fi/handle/11111/46106
dc.identifier.urlhttps://www.nature.com/articles/s41408-023-00831-9
dc.identifier.urnURN:NBN:fi-fe2025082784970
dc.language.isoen
dc.okm.affiliatedauthorJyrkkiö, Sirkku
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSPRINGERNATURE
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber62
dc.relation.doi10.1038/s41408-023-00831-9
dc.relation.ispartofjournalBlood Cancer Journal
dc.relation.volume13
dc.source.identifierhttps://www.utupub.fi/handle/10024/183334
dc.titleTransformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
JyrkkiöEtAl2023TransformationAndSurvivalInMarginalZoneLymphoma.pdf
Size:
1.22 MB
Format:
Adobe Portable Document Format